Affiliation: University of Rochester
- Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialIra Shoulson
University of Rochester Medical Center, Rochester, NY 14620, USA
Ann Neurol 51:604-12. 2002....
- Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROSAnnie Killoran
University of Rochester, Rochester, NY, USA
Neurology 80:2022-7. 2013..We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study...
- Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid
Department of Neurology, University of Rochester, Rochester, New York, USA
Mov Disord 25:1801-8. 2010..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
- A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 24:2081-90. 2009..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
- The relationship between CAG repeat length and clinical progression in Huntington's diseaseBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 23:1223-7. 2008..This finding may account for the variable results from previous studies examining CAGn and progression. Adjusting for CAGn may be important for clinical trials...
- Fatigue in levodopa-naive subjects with Parkinson diseaseG Schifitto
University of Rochester, NY, USA
Neurology 71:481-5. 2008..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial...
- Depressed mood and suicidality in individuals exposed to tetrabenazine in a large huntington disease observational studyE Ray Dorsey
Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY, USA
J Huntingtons Dis 2:509-15. 2013..Tetrabenazine, a treatment for chorea in Huntington disease, carries a boxed warning due to safety, especially related to suicidality...
- Altered cholesterol and fatty acid metabolism in Huntington diseaseRobert C Block
Division of Epidemiology, Department of Community and Preventive Medicine and Preventive Cardiology Unit, Box 644, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14620, USA
J Clin Lipidol 4:17-23. 2010..Drugs that combat the dysregulated lipid milieu in Huntington disease may help treat this perplexing and catastrophic genetic disease...
- Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD studyKevin M Biglan
University of Rochester, Rochester, New York, USA
Mov Disord 24:1763-72. 2009..Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials...
- Therapeutic directions for Parkinson's diseaseIra Shoulson
Department of Neurology, University of Rochester, Rochester, New York 14620, USA
Mov Disord 25:S152-4. 2010..These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples...
- Communicating clinical trial results to research participantsE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
Arch Neurol 65:1590-5. 2008..Communicating clinical trial results to research participants is seldom accomplished in a timely or an effective manner...
- Sociology of collaborative research groupsIra Shoulson
University of Rochester School of Medicine and Dentistry, NY 14620, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:118-20. 2004
- Rasagiline improves quality of life in patients with early Parkinson's diseaseKevin M Biglan
Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
Mov Disord 21:616-23. 2006..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
- Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional declineClifford W Shults
Department of Neurosciences, Mail Code 0662, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0662, USA
Arch Neurol 59:1541-50. 2002..Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression...
- Measuring the effects of therapy in Parkinson diseaseClifford W Shults
JAMA 291:2430-1; author reply 2431. 2004
- Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson diseaseWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
Hypertension 52:587-93. 2008..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...
- A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuationsKaren Blindauer
Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
Arch Neurol 63:210-6. 2006..Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration...
- Levodopa and the progression of Parkinson's diseaseStanley Fahn
Columbia University, New York, USA
N Engl J Med 351:2498-508. 2004..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
- Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trialConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 23:653-9; quiz 776. 2008..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
- Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatmentsNicholas H G Holford
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
J Pharmacokinet Pharmacodyn 33:281-311. 2006..We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression...
- Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida
Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
Mov Disord 21:1716-21. 2006..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
- A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank
Department of Neurology, Boston University School of Medicine, Boston, MA, USA
Clin Neuropharmacol 31:127-33. 2008..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
- Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trialAndrew Siderowf
Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 17:758-63. 2002..The findings are in agreement with previous reports on interrater reliability...
- Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studiesJames Swanson
University of California, Irvine, Department of Pediatrics, Child Development Center, CA, USA
Arch Gen Psychiatry 60:204-11. 2003..Tachyphylaxis was hypothesized to account for the reduced effects, and an ascending drug delivery pattern was proposed to overcome this acute tolerance...
- Verbal episodic memory declines prior to diagnosis in Huntington's diseaseAndrea C Solomon
Department of Psychological and Brain Sciences, Indiana University, 1101 E 10th Street, Bloomington, IN 47405, USA
Neuropsychologia 45:1767-76. 2007..These findings indicate that verbal episodic memory is affected in early pre-diagnostic HD and may decline as striatal volumes decrease and individuals approach the motor diagnostic threshold...
- Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
Arch Neurol 65:716-23. 2008..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
- Interrater agreement in the assessment of motor manifestations of Huntington's diseasePenelope Hogarth
Oregon Health and Science University, Portland, Oregon 97239 3098, USA
Mov Disord 20:293-7. 2005..We expect these findings to translate to a similar level of interobserver agreement in the clinical trial setting involving experienced investigators examining live patients...
- Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventionsChristopher G Goetz
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 23:690-9. 2008..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials...